MCIA Inc Has $1.76 Million Holdings in Zoetis Inc. (NYSE:ZTS)

MCIA Inc lowered its stake in shares of Zoetis Inc. (NYSE:ZTSGet Rating) by 12.3% in the first quarter, Holdings reports. The firm owned 9,116 shares of the company’s stock after selling 1,274 shares during the period. MCIA Inc’s holdings in Zoetis were worth $1,755,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Investment Research & Advisory Group Inc. purchased a new position in Zoetis during the 4th quarter worth $26,000. Consolidated Planning Corp bought a new stake in Zoetis in the 3rd quarter worth about $28,000. Amplius Wealth Advisors LLC purchased a new stake in Zoetis in the 4th quarter valued at about $31,000. Aquire Wealth Advisors LLC bought a new position in shares of Zoetis during the 4th quarter worth approximately $32,000. Finally, City State Bank purchased a new position in shares of Zoetis in the 4th quarter worth approximately $36,000. Institutional investors and hedge funds own 90.73% of the company’s stock.

NYSE ZTS traded up $1.99 during trading on Wednesday, hitting $164.00. 11,950 shares of the company’s stock traded hands, compared to its average volume of 1,745,750. The company has a debt-to-equity ratio of 1.12, a quick ratio of 1.58 and a current ratio of 2.25. The stock has a market capitalization of $77.18 billion, a price-to-earnings ratio of 37.16, a PEG ratio of 2.67 and a beta of 0.77. Zoetis Inc. has a 12-month low of $154.18 and a 12-month high of $249.27. The business has a 50 day moving average of $170.11 and a 200-day moving average of $193.14.

Zoetis (NYSE:ZTSGet Rating) last announced its quarterly earnings results on Thursday, May 5th. The company reported $1.32 EPS for the quarter, beating analysts’ consensus estimates of $1.22 by $0.10. Zoetis had a net margin of 26.27% and a return on equity of 49.62%. The company had revenue of $2 billion for the quarter, compared to analysts’ expectations of $1.98 billion. During the same period in the prior year, the company posted $1.26 EPS. Zoetis’s revenue was up 6.9% compared to the same quarter last year. On average, analysts expect that Zoetis Inc. will post 5.05 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 1st. Stockholders of record on Thursday, July 21st will be given a $0.325 dividend. The ex-dividend date is Wednesday, July 20th. This represents a $1.30 dividend on an annualized basis and a dividend yield of 0.79%. Zoetis’s dividend payout ratio (DPR) is currently 29.82%.

In other news, EVP Roxanne Lagano sold 2,167 shares of the business’s stock in a transaction dated Tuesday, April 26th. The stock was sold at an average price of $178.96, for a total value of $387,806.32. Following the completion of the sale, the executive vice president now owns 23,687 shares of the company’s stock, valued at approximately $4,239,025.52. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Willie M. Reed sold 1,855 shares of the firm’s stock in a transaction that occurred on Friday, June 10th. The stock was sold at an average price of $162.31, for a total value of $301,085.05. Following the transaction, the director now owns 6,782 shares in the company, valued at $1,100,786.42. The disclosure for this sale can be found here. 0.12% of the stock is owned by insiders.

ZTS has been the topic of a number of recent analyst reports. The Goldman Sachs Group dropped their price target on Zoetis from $237.00 to $208.00 and set a “buy” rating on the stock in a report on Thursday, May 19th. Citigroup lowered their target price on Zoetis from $232.00 to $208.00 and set a “neutral” rating on the stock in a research note on Wednesday, March 9th. Finally, lowered shares of Zoetis from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, April 26th. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $230.43.

About Zoetis (Get Rating)

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Featured Stories

Want to see what other hedge funds are holding ZTS? Visit to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTSGet Rating).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with's FREE daily email newsletter.